ArticleThe Journal of clinical investigation2018
Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Angiogenic Doping: Plausible Yet Difficult to Detect.Sports medicine (Auckland, N.Z.) · 2026Review
- BMP6 as a therapeutic target for preeclampsia: enhancing trophoblast invasion and vascular mimicry.Cellular and molecular life sciences : CMLS · 2026Article
- Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026Review
- Placental Igf1 overexpression sex-specifically impacts mouse placenta structure, altering offspring striatal development and behavior.Experimental neurology · 2025Article
- Sex Differences in Hypertension Risk: Insights from Placental Genomics and Pregnancy-Driven Vascular Programming.International journal of molecular sciences · 2025Review
- Current Approaches and Innovations in Managing Preeclampsia: Highlighting Maternal Health Disparities.Journal of clinical medicine · 2025Review
- Plasma cell-free extrachromosomal circular DNA is a molecular hallmark of preeclampsia.Computational and structural biotechnology journal · 2025Article
- The role of placental hormones and metabolites in modulating uterine circulation in physiological and pathological pregnancies.Frontiers in endocrinology · 2025Review
- Risk of preeclampsia in pregnant individuals with chronic kidney disease: a framework from Chinese cohort.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Two decades of advances in preeclampsia research: molecular mechanisms and translational studies.The Journal of clinical investigation · 2024Article
- Molecular regulators of defective placental and cardiovascular development in fetal growth restriction.Clinical science (London, England : 1979) · 2024Review
- Alleviation of preeclampsia-like symptoms through PlGF and eNOS regulation by hypoxia- and NF-κB-responsive miR-214-3p deletion.Experimental & molecular medicine · 2024Article
- Deciphering the Epigenetic Landscape: Placental Development and Its Role in Pregnancy Outcomes.Stem cell reviews and reports · 2024Review
- Trophectoderm biopsy of blastocysts following IVF and embryo culture increases epigenetic dysregulation in a mouse model.Human reproduction (Oxford, England) · 2024Article
- Coffee intake leads to preeclampsia-like syndromes in susceptible pregnant rats.Journal of nutritional science · 2024Article
- MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia.International journal of molecular sciences · 2023Article
- Growth-Restricted Fetuses and Offspring Reveal Adverse Sex-Specific Metabolic Responses in Preeclamptic Mice Expressing Human sFLT1.International journal of molecular sciences · 2023Article
- IL11 activates the placental inflammasome to drive preeclampsia.Frontiers in immunology · 2023Article
- Pathophysiology of Preeclampsia and L-Arginine/L-Citrulline Supplementation as a Potential Strategy to Improve Birth Outcomes.Advances in experimental medicine and biology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
Preeclampsia remains a clinical challenge due to its poorly understood pathogenesis. A prevailing notion is that increased placental production of soluble fms-like tyrosine kinase-1 (sFlt-1) causes the maternal syndrome by inhibiting proangiogenic placental growth factor (PlGF) and VEGF. However, the significance of PlGF suppression in preeclampsia is uncertain. To test whether preeclampsia results from the imbalance of angiogenic factors reflected by an abnormal sFlt-1/PlGF ratio, we studied PlGF KO (Pgf-/-) mice and noted that the mice did not develop signs or sequelae of preeclampsia despite a marked elevation in circulating sFLT-1. Notably, PlGF KO mice had morphologically distinct placentas, showing an accumulation of junctional zone glycogen. We next considered the role of placental PlGF in an established model of preeclampsia (pregnant catechol-O-methyltransferase-deficient [COMT-deficient] mice) by generating mice with deletions in both the Pgf and Comt genes. Deletion of placental PlGF in the context of COMT loss resulted in a reduction in maternal blood pressure and increased placental glycogen, indicating that loss of PlGF might be protective against the development of preeclampsia. These results identify a role for PlGF in placental development and support a complex model for the pathogenesis of preeclampsia beyond an angiogenic factor imbalance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.